MK0869, aprepitant
MK0869, aprepitant is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Clinical Trials (6)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6